Aethlon MedicalAEMD -6.07%23 Current Ratio is 3.85 as of Mar. 2026, which is 32% below its 10-year median of 5.69. GuruFocus rates AEMD with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, Aethlon Medical ranks better than 68.27% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Aethlon Medical's current ratio for the quarter that ended in Mar. 2026 was 3.85.
Aethlon Medical has a current ratio of 3.85. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Aethlon Medical's Current Ratio or its related term are showing as below:
AEMD'
s Current Ratio Range Over the Past 10 Years
Min: 2.21 Med: 5.69 Max: 15.13
Current: 3.85
During the past 13 years, Aethlon Medical's highest Current Ratio was 15.13. The lowest was 2.21. And the median was 5.69.
AEMD's Current Ratio is ranked better than 68.27% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs AEMD: 3.85
Aethlon Medical (NAS:AEMD) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Aethlon Medical Current Ratio Related Terms
Aethlon Medical Current Ratio Historical Data
* Premium members only.
The historical data trend for Aethlon Medical's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AEMD vs VYCO, RBOT, ESMC: Current Ratio Comparison
For the Medical Devices subindustry, Aethlon Medical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aethlon Medical Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's Current Ratio distribution charts can be found below:
* The bar in red indicates where Aethlon Medical's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aethlon Medical (AEMD) has a Current Ratio of 3.85 as of Mar. 2026. This is 32% below median its historical median of 5.69. Over the past decade, Aethlon Medical's Current Ratio has ranged from 2.21 to 15.13. According to the industry distribution chart, Aethlon Medical ranks #271 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Aethlon Medical's Current Ratio too high?
Aethlon Medical's current Current Ratio of 3.85 is 32% below median its 10-year median of 5.69. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 15.13. The Medical Devices & Instruments industry median Current Ratio is 2.49. Aethlon Medical's value of 3.85 is 54.6% above this industry median. Based on the distribution chart, Aethlon Medical ranks #271 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aethlon Medical has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's Current Ratio compare to VYCO and RBOT?
According to the Medical Devices & Instruments industry distribution chart, Aethlon Medical ranks #271 out of 854 companies for Current Ratio. This puts Aethlon Medical in the upper half of its industry. The industry median Current Ratio is 2.49. Aethlon Medical's value of 3.85 is 54.6% above this benchmark. Historically, Aethlon Medical's own Current Ratio has ranged from 2.21 to 15.13 over the past decade. While the company's 10-year median is 5.69 vs. the industry median of 2.49, Aethlon Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aethlon Medical's current Current Ratio of 3.85 is 54.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aethlon Medical's current Current Ratio is 3.85, which is 32% below median its own 10-year median of 5.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current Current Ratio of 3.85. The current Current Ratio is 3.85, which is 32% below median its 10-year median of 5.69 and 54.6% above the Medical Devices & Instruments industry median of 2.49. Aethlon Medical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current Current Ratio is 3.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
23GF Score
Get the complete analysis for AEMD
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEMD has been successfully added to your 
